[CEO Story]AACR-KCA Joint Conference 2021

15 Nov 2021
TitleAACR-KCA Joint Conference 2021
CategoryCEO Story

AACR-KCA Joint Conference 2021

PharmAbcine, a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented e-poster presentations on the nonclinical data of PMC-403, a vessel normalizing antibody candidate, and PMC-309, a novel VISTA-targeting antibody candidate, at AACR-KCA November 11-12, 2021 (KST).

AACR-KCA is a joint conference with AACR (American Association for Cancer Research) and KCA (Korean Cancer Association), and this year’s 2nd annual conference was on precision medicine in solid tumors.

The e-posters highlighted the vessel normalization effects of PMC-403 in ophthalmology animal models and enhanced anti-tumor effects of PMC-309 when used in combo with the existing drugs.

■  Visit the link below for the event.


     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea

     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 

     COPYRIGHT BY PharmAbcine Inc.